Published in J Cereb Blood Flow Metab on June 04, 2014
Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system. Front Cell Neurosci (2015) 0.83
A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia. Front Cell Neurosci (2016) 0.80
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice. J Cereb Blood Flow Metab (2015) 0.77
Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3 (Bethesda) (2016) 0.77
Platelet-Derived Growth Factor Receptor-β Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice. Crit Care Med (2016) 0.77
Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin. Cell Discov (2017) 0.75
The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis. PLoS One (2016) 0.75
Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells. FEBS Open Bio (2016) 0.75
2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. Arterioscler Thromb Vasc Biol (2016) 0.75
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. J Thromb Haemost (2016) 0.75
Role of PDGF-D and PDGFR-β in neuroinflammation in experimental ICH mice model. Exp Neurol (2016) 0.75
Editorial: The Role of the Plasminogen Activating System in Neurobiology. Front Cell Neurosci (2016) 0.75
Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa. J Am Heart Assoc (2017) 0.75
Regulation of Dipeptidyl Peptidase IV in the Post-stroke Rat Brain and In Vitro Ischemia: Implications for Chemokine-Mediated Neural Progenitor Cell Migration and Angiogenesis. Mol Neurobiol (2016) 0.75
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Astrocytes induce blood-brain barrier properties in endothelial cells. Nature (1987) 4.70
The plasminogen activator/plasmin system. J Clin Invest (1991) 4.20
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med (1998) 4.09
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke (1997) 3.94
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest (2003) 3.41
Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol (2007) 3.33
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med (2003) 3.10
Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem (1999) 3.06
Molecular mechanisms of fibrinolysis. Br J Haematol (2005) 3.03
Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell (1997) 2.68
JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci (2009) 2.64
Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab (2005) 2.45
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 2.30
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 2.22
Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci (2003) 2.21
An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci (1997) 2.03
Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost (2001) 1.98
Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost (1981) 1.98
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
Extracellular proteolysis in the adult murine brain. J Clin Invest (1993) 1.96
Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke (2003) 1.95
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis (2010) 1.90
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J (1997) 1.85
Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther (2011) 1.81
Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus (2007) 1.78
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke (2005) 1.77
Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry (1999) 1.73
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke (2000) 1.71
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta (1979) 1.69
Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood (2009) 1.61
Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry (1998) 1.55
Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron (2006) 1.54
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J Cereb Blood Flow Metab (2006) 1.49
Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry (2008) 1.46
Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem (2006) 1.40
The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A (2003) 1.40
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
Plasmin as a proinflammatory cell activator. J Leukoc Biol (2012) 1.38
Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur J Neurosci (2001) 1.37
Rapid loss of microvascular integrin expression during focal brain ischemia reflects neuron injury. J Cereb Blood Flow Metab (2001) 1.37
Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis (2008) 1.37
Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. J Neurosci (1995) 1.37
Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol (2004) 1.36
Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation (2002) 1.34
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke (2001) 1.32
Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation (2005) 1.32
Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci (2002) 1.31
Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation. J Biol Chem (1988) 1.31
S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci (2005) 1.29
Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost (1989) 1.28
Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab (2003) 1.28
Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse. PLoS One (2010) 1.28
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab (2009) 1.26
Thrombolytic agents. Thromb Haemost (2005) 1.25
The cardiovascular actions of protease-activated receptors. Mol Pharmacol (2004) 1.25
Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci (2011) 1.23
Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost (2005) 1.23
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood (2002) 1.22
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost (2007) 1.22
The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol (2000) 1.21
Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice. J Neurosci (2007) 1.19
Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke (2005) 1.18
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke (2008) 1.17
Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res (1990) 1.14
Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke (2003) 1.14
Characterization of the murine plasma fibrinolytic system. Eur J Biochem (1994) 1.14
Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia (2002) 1.14
Plasminogen activator in the rodent brain. Brain Res (1981) 1.13
Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol (2002) 1.12
The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci (2010) 1.11
Laminin degradation by plasmin regulates long-term potentiation. J Neurosci (2000) 1.11
Plasminogen has a broad extrahepatic distribution. Thromb Haemost (2002) 1.11
Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (2008) 1.10
Plasminogen receptors: the first quarter century. Semin Thromb Hemost (2013) 1.09
Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J Biol Chem (2008) 1.09
Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol (1994) 1.08
t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood (2012) 1.08
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain (2012) 1.04
Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: an MR imaging permeability study. AJNR Am J Neuroradiol (2009) 1.03
Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost (2004) 1.03
A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem (2004) 1.03
The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. J Biol Chem (2010) 1.02
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res (2011) 1.01
Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation (1998) 1.01
Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology (2010) 1.00
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One (2010) 1.00
Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol (2012) 0.99
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab (2011) 0.99
Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke (2006) 0.98
Acute tissue damage after injections of thrombin and plasmin into rat striatum. Stroke (2001) 0.98
Plasminogen activator inhibitor type 2: still an enigmatic serpin but a model for gene regulation. Methods Enzymol (2011) 0.88